Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2009

View Archived Issues

TLK-58747, a DNA alkylator, shows broad antitumor activity and less toxicity in preclinical studies

CpG-28 appears to benefit some recurrent glioblastoma patients in phase II study

Small-molecule mTOR inhibitor AZD-8055 shows potent antitumor activity in preclinical studies

Sanofi-aventis and DNDi sign collaboration agreement for fexinidazole for sleeping sickness

GSK presents update on development of A (H1N1) adjuvanted influenza vaccine

Merck Serono withdraws offer for reproductive technology company MediCult

PF-3084014 displays preclinical antitumor activity in several models

GlaxoSmithKline targets AKT1 with GSK-1720070

Second generation proteasome inhibitor developed at Millennium Pharmaceuticals

Novel polyene compound, corifungin, displays potent antifungal activity in vitro

Biovail acquires worldwide rights to tetrabenazine from Cambridge Laboratories

Biopure presents an update on the NMRC's clinical development of Hemopure

Genentech and Biogen Idec submit two sBLAs to FDA for Rituxan in CLL

GW Pharmaceuticals files regulatory submission in the U.K. and Spain for Sativex in MS

IDMB recommends continuation of phase III AGENDA trial of Genta's Genasense

Endotis Pharma reports successful completion of phase I EP-42675 program

Janssen claims novel adenosine A2A receptor antagonists for neurodegenerative conditions

Merck KGaA discovers SGLT inhibitors for the treatment of diabetes

Preclinical studies point to potential of GS-9411 for cystic fibrosis

Eisai claims novel cytidine deaminase inhibitors for the treatment of cancer

Active first quarter at Bristol-Myers Squibb

Younger macular degeneration patients more likely to benefit from VEGF Trap-Eye

Potassium channel blocker WYE-160020 reduces atrial fibrillation inducibility in canine models

Pharmacologic chaperone of mutant opsin, BIK-381, for the treatment of retinal degeneration

Mipomersen study meets endpoints in homozygous familial hypercholesterolemia

First two stages of Verona's phase I/IIa RPL-554 trial yields positive results

FDA grants orphan drug designation for MediGene's EndoTAG-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...